Breaking News, Collaborations & Alliances

Moderna, Novocol Pharma Partner on Fill-Finish Agreement for mRNA Vaccines

Vaccines manufactured at Moderna's state-of-the-art Canadian mRNA facility to be prepared and packaged at Novocol's Ontario-based facility.

Moderna, Inc., a provider of messenger RNA (mRNA) therapeutics and vaccines, entered into a long-term agreement with Ontario-based Novocol Pharma, a sterile injectable contract development and manufacturing organization (CDMO), to perform aseptic fill-finish, labelling and packaging of mRNA respiratory vaccines expected to be produced in Canada. The agreement with Novocol Pharma will result in the fill-finish capacity of vaccines manufactured at Moderna’s Laval-based mRNA facility, whic...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters